Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › ELIXA

ELIXA

Lixisenatide · T2D after ACS

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Lixisenatide
Population
T2D after ACS
Official title
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
Sponsor
Sanofi
Phase
Phase 3
Registry status
completed · 2010-06 → 2015-02
Participants
6068
Registry
NCT01147250

Cardiovascular and kidney outcomes

ELIXA lixisenatide 20 µg vs placebo · T2D after ACS · n = 6068 · 2015 verified

EndpointHR95 % CIEvents, drug vs controlStatus
4-point MACE primary
CV death, nonfatal MI, nonfatal stroke, or hospitalization for unstable angina (first occurrence)
1.020.89–1.17406 vs 399verified
Cardiovascular death
Death from cardiovascular causes
0.980.78–1.22156 vs 158verified
All-cause death
Death from any cause
0.940.78–1.13211 vs 223verified
Myocardial infarction
Fatal or nonfatal myocardial infarction
1.030.87–1.22270 vs 261verified
Stroke
Fatal or nonfatal stroke
1.120.79–1.5867 vs 60verified
Hospitalisation for heart failure
Hospitalization for heart failure
0.960.75–1.23122 vs 127verified
Expanded MACE (MACE + HF hosp. + revasc. + UA)
Primary end point (CV death, nonfatal MI, nonfatal stroke, hospitalization for unstable angina), hospitalization for heart failure, or coronary revascularization
1.000.90–1.11661 vs 659verified
Expanded MACE (MACE + HF hosp. + UA)
Primary end point (CV death, nonfatal MI, nonfatal stroke, hospitalization for unstable angina) or hospitalization for heart failure
0.970.85–1.10456 vs 469verified
Hospitalisation for unstable angina
Hospitalization for unstable angina (component of the 4-point primary end point; all events, not first-event contribution)
1.110.47–2.6211 vs 10verified
Verbatim quotes (9)
  • 4-point MACE · Abstract, Results; Table 2
    A primary end-point event occurred in 406 patients (13.4%) in the lixisenatide group and in 399 (13.2%) in the placebo group (hazard ratio, 1.02; 95% confidence interval [CI], 0.89 to 1.17)
  • Cardiovascular death · Results, Cardiovascular End Points; Table 2
    A total of 156 patients in the lixisenatide group and 158 in the placebo group died from cardiovascular causes (hazard ratio, 0.98; 95% CI, 0.78 to 1.22)
  • All-cause death · Results, Cardiovascular End Points; Table 2
    Death from any cause was reported in 211 patients (7.0%) in the lixisenatide group and in 223 (7.4%) in the placebo group (hazard ratio, 0.94; 95% CI, 0.78 to 1.13)
  • Myocardial infarction · Results, Cardiovascular End Points; Table 2
    270 patients in the lixisenatide group and 261 in the placebo group had a fatal or nonfatal myocardial infarction (hazard ratio, 1.03; 95% CI, 0.87 to 1.22)
  • Stroke · Results, Cardiovascular End Points; Table 2
    67 patients in the lixisenatide group and 60 in the placebo group had a fatal or nonfatal stroke (hazard ratio, 1.12; 95% CI, 0.79 to 1.58)
  • Hospitalisation for heart failure · Results, Cardiovascular End Points; Table 2
    hospitalization for heart failure occurred in 122 patients (4.0%) in the lixisenatide group and in 127 (4.2%) in the placebo group (hazard ratio, 0.96; 95% CI, 0.75 to 1.23)
  • Expanded MACE (MACE + HF hosp. + revasc. + UA) · Table 2 (secondary end points)
    Primary end-point event, hospitalization for heart failure, or revascularization   659 (21.7) 11.2   661 (21.8) 11.1 1.00 (0.90–1.11)
  • Expanded MACE (MACE + HF hosp. + UA) · Results, Cardiovascular End Points paragraph; Table 2 (secondary end points)
    in this expanded end point (hazard ratio, 0.97; 95% CI, 0.85 to 1.10)
  • Hospitalisation for unstable angina · Results, Cardiovascular End Points paragraph; Table 2
    hospi- talized for unstable angina (hazard ratio, 1.11; 95% CI, 0.47 to 2.62)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: ELIXA. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/elixa/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.